Swiss healthcare company Galenica said on Monday that its kidney drug PA21 successfully met primary and secondary endpoints in a late-stage trial, paving the way for regulatory filings in the United States, Europe and Switzerland.

Results of the six-month phase III study found that maintenance doses of PA21 were superior in sustaining the phosphate-lowering effect in patients with chronic kidney disease who are on dialysis versus a PA21 inactive low dose.

The company plans to submit PA21, which it developed in collaboration with Fresenius Medical Care, for regulatory approval in the fourth-quarter of 2012.